Scinai Immunotherapeutics (SCNI) Net Cash Flow (2018 - 2024)

Scinai Immunotherapeutics has disclosed Net Cash Flow across 7 years of filings, most recently posting $924000.0 for Q4 2024.

• Net Cash Flow for Q4 2024 came in at $924000.0, up 163.33% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.1 million (up 74.42% YoY), and the FY2025 annual result was -$285000.0, up 90.19% from the prior year.
• Net Cash Flow came in at $924000.0 for Q4 2024 at Scinai Immunotherapeutics, up from -$2.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $11.4 million in Q1 2021 to a low of -$15.9 million in Q4 2020.
• The 5-year median for Net Cash Flow is -$2.0 million (2024), against an average of -$2.8 million.
• Across the five-year window, Net Cash Flow slumped 208.98% in 2020 and surged 163.33% in 2024, its largest moves.
• Scinai Immunotherapeutics' Net Cash Flow stood at -$15.9 million in 2020, then jumped by 143.48% to $6.9 million in 2021, then sank by 112.48% to -$863000.0 in 2022, then slumped by 69.06% to -$1.5 million in 2023, then soared by 163.33% to $924000.0 in 2024.
• The last three Net Cash Flow figures came in at $924000.0 (Q4 2024), -$2.0 million (Q3 2024), and -$1.8 million (Q2 2024), per Business Quant data.